189 related articles for article (PubMed ID: 29336300)
21. Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
Garcia Spezza E; Brethon B; Petit A; Mazingue F; Gandemer V; Boissel N; Carausu L; Reguerre Y; Leverger G; Ducassou S
Br J Haematol; 2020 Jan; 188(1):170-173. PubMed ID: 31808943
[No Abstract] [Full Text] [Related]
22. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
23. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
24. Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
Testi AM; Mohamed S; Diverio D; Piciocchi A; Menna G; Rizzari C; Timeus F; Micalizzi C; Lo Nigro L; Santoro N; Masetti R; Micheletti MV; Ziino O; Onofrillo D; Ladogana S; Putti C; Pierani P; Arena V; Zecca M; Foà R; Locatelli F
Br J Haematol; 2021 Oct; 195(2):278-283. PubMed ID: 34145572
[No Abstract] [Full Text] [Related]
25. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
26. Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia.
Xu X; Mao Y; Zhu X; Tang F
Pak J Pharm Sci; 2022 Jan; 35(1):23-28. PubMed ID: 35221268
[TBL] [Abstract][Full Text] [Related]
27. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
[TBL] [Abstract][Full Text] [Related]
28. Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
Wiernik PH
Br J Haematol; 2023 Jan; 200(2):126-127. PubMed ID: 36342482
[TBL] [Abstract][Full Text] [Related]
29. Differentiation therapy revisited.
de Thé H
Nat Rev Cancer; 2018 Feb; 18(2):117-127. PubMed ID: 29192213
[TBL] [Abstract][Full Text] [Related]
30. The simpler, the better: oral arsenic for acute promyelocytic leukemia.
Zhu HH; Hu J; Lo-Coco F; Jin J
Blood; 2019 Aug; 134(7):597-605. PubMed ID: 31113776
[TBL] [Abstract][Full Text] [Related]
31. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
32. Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid.
Autore F; Chiusolo P; Sorà F; Giammarco S; Laurenti L; Innocenti I; Metafuni E; Piccirillo N; Pagano L; Bacigalupo A; Leone G; Sica S
Leuk Lymphoma; 2019 May; 60(5):1328-1330. PubMed ID: 30526180
[No Abstract] [Full Text] [Related]
33. Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia.
Kulkarni UP; Selvarajan S; Lionel S; Prakash MA; Palani HK; Balasundaram N; Venkataraman A; Korula A; Devasia AJ; Fouzia NA; Janet NB; Nair SC; Abraham A; Mani T; Lakshmanan J; Arunachalam AK; Balasubramanian P; George B; Mathews V
Blood Cancer J; 2022 Jan; 12(1):22. PubMed ID: 35102152
[No Abstract] [Full Text] [Related]
34. Successful Treatment of Acute Promyelocytic Leukemia Complicated with Endometrial Cancer by Arsenic Trioxide.
Sugiura H; Nishimori H; Matsuoka H; Nakamura K; Fujii K; Fujii N; Matsuoka KI; Maeda Y
Acta Med Okayama; 2021 Apr; 75(2):219-224. PubMed ID: 33953429
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Lin CP; Huang MJ; Chang IY; Lin WY
Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.
Cicconi L; Platzbecker U; Avvisati G; Paoloni F; Thiede C; Vignetti M; Fazi P; Ferrara F; Divona M; Albano F; Efficace F; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Annibali O; Wattad M; Lubbert M; Brandts CH; Hanel M; Rollig C; Schmitz N; Link H; Frairia C; Fozza C; Maria D'Arco A; Di Renzo N; Cortelezzi A; Fabbiano F; Dohner K; Ganser A; Dohner H; Amadori S; Mandelli F; Voso MT; Ehninger G; Schlenk RF; Lo-Coco F
Leukemia; 2020 Mar; 34(3):914-918. PubMed ID: 31611624
[No Abstract] [Full Text] [Related]
37. JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL).
Fujita H; Ishikawa Y; Yokoyama Y
Int J Hematol; 2020 Jun; 111(6):747-760. PubMed ID: 32347422
[No Abstract] [Full Text] [Related]
38. Cutaneous herald: leukaemia cutis as presenting manifestation of relapse in acute promyelocytic leukaemia.
Balasubramanian P; Nampoothiri RV; Goni D; Malhotra P
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29724869
[TBL] [Abstract][Full Text] [Related]
39. Differentiation syndrome in acute promyelocytic leukaemia.
Stahl M; Tallman MS
Br J Haematol; 2019 Oct; 187(2):157-162. PubMed ID: 31410848
[TBL] [Abstract][Full Text] [Related]
40. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Tsimberidou AM; Kantarjian H; Keating MJ; Estey E
Leuk Lymphoma; 2006 Nov; 47(11):2282-8. PubMed ID: 17107899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]